Sarepta's stock drops on ELEVIDYS safety concerns, yet potential remains for ambulatory patients. Click here to read an analysis of SRPT stock now.

Stocks were rising Monday after The Wall Street Journal reported Tehran was looking to resume talks with the White House over its nuclear program in order to de-escalate a military conflict with Israel.

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other parents still push for the therapy.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with Duchenne muscular dystrophy,

Shares of Sarepta Therapeutics, Inc. SRPT fell sharply in today's pre-market trading after the company suspended ELEVIDYS shipments and paused ENVISION trial after second fatal liver failure in non-ambulatory Duchenne patients. Sarepta Therapeutics shares tumbled 31.4% to $24.86 in the pre-market trading session.

Wall Street analysts were quick to downgrade Sarepta Therapeutics (NASDAQ:SRPT) on Monday as the company suspended its revenue guidance for 2025 following a second fatality linked to Elevidys, its gene therapy for Duchenne muscular dystrophy.